Expression of MAS1 in breast cancer

Yi Luo,1 Eriko Tanabe,1 Misaho Kitayoshi,1 Yukiko Nishiguchi,1 Rina Fujiwara,1 Sayako Matsushima,1 Takamitsu Sasaki,2 Tomonori Sasahira,1 Yoshitomo Chihara,1 Dai Nakae,3 Kiyomu Fujii,1 Hitoshi Ohmori1 and Hiroki Kuniyasu1

1Department of Molecular Pathology, Nara Medical University, Kashihara; 2Department of Gastroenterological Surgery, Fukuoka University School of Medicine, Fukuoka; 3Department of Nutritional Science and Food Safety, Faculty of Applied Biosciences, Tokyo University of Agriculture, Tokyo, Japan

Key words
ACE2, angiotensin, angiotensin1-7, breast cancer, MAS1

Correspondence
Hiroki Kuniyasu, Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.
Tel: +81-744-22-3051; Fax: +81-744-25-7308; E-mail: cooninh@zb4.so-net.ne.jp

Funding information
Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, Japan Ministry of Health, Labour and Welfare of Japan

Received October 30, 2014; Revised May 28, 2015; Accepted June 7, 2015

Cancer Sci 106 (2015) 1240–1248
doi: 10.1111/cas.12719

MAS1 is a receptor for angiotensin 1-7 (A1-7), which is derived from angiotensin II (A-II) by the action of angiotensin converting enzyme (ACE). MAS1 directly inhibits A-II type 1 receptor (AT1R) to provide vasoconstriction and hypertension. In cancer, AT1R is upregulated and plays a key role in cell proliferation, survival, invasion, angiogenesis and subsequent metastasis. AT2R is a subtype of alternative A-II receptor, which elicits the opposite effects from AT1R in certain cancer cells. Therefore, AT1R and AT2R have opposite effects on vasculature compared to AT1R; namely, vasoconstriction and hypertension. In contrast, AT2R shows antitumoral effects at high A-II concentrations.

Through other pathways, angiotensin 1-7 (A1-7) is produced from A-I by CD10 (neprilysin) or from A-II by ACE2. MAS1 is a receptor for A1-7 and A-II, which elicits the opposite effects on vasculature compared to AT1R; namely, vasoconstriction and hypotension. The MAS1–A1-7 axis has, moreover, been implicated in certain cancers such as CRC.

Breast cancer is the fourth leading cause of cancer death in Japanese women. The treatment of breast cancer commonly includes a combination of surgery, radiation, chemotherapy, hormone therapy and targeted therapy against human epidermal growth factor receptor-2 (HER2). When adopting hormone therapy or HER2 targeted therapy, the expression of estrogen receptor (ER), progesterone receptor (PgR) or HER2 should be evaluated. In triple-negative breast cancer (TNBC), expressions of ER, PgR and HER2 are lost in all cancer cells. TNBC represent approximately 15% of all breast cancers. TNBC shows rapid growth and a high frequency of recurrence and metastasis. Accordingly, it is associated with high mortality and poor prognosis. Currently, adjuvant therapies, including targeting of epidermal growth factor receptor (EGFR) and poly (ADP-ribose) polymerase 1, are being developed to treat this breast cancer subtype. Identifying a novel molecular target is an important issue for the treatment of TNBC.

In the present study, we aim to elucidate the expression and tumor-inhibitory role of MAS1, and discuss its potential as a molecular target for treatment of breast cancer, including TNBC.

Materials and Methods

Surgical specimens. Formalin-fixed surgical specimens from 158 patients (21 benign mammary lesions, including mastopathy, usual duct hyperplasia or intraductal papilloma, 10 ductal carcinomas in situ [DCIS], and 132 invasive ductal carcinomas [IDC]) diagnosed at the Department of Molecular Pathology, Nara Medical School were randomly selected. Because written informed consent was not obtained, any identifying information
was removed from the samples before analysis to ensure strict privacy protection (unlinkable anonymization). All procedures were performed in accordance with the Ethical Guidelines for Human Genome/Gene Research enacted by the Japanese Government, which was approved by the Ethics Committee of Nara Medical University (Authorization Number 937).

**Tissue array.** Tissue array slides of TNBC were obtained from US Biomax (BR487a, Rockville, MD, USA). Quadruplet slides were immunostained with ER, PgR, Her2 and MAS1. IDC cases with triple negative expression (36 cases) were used for comparison between clinicopathological parameters and MAS1 expression.

**Cell culture and reagents.** The 4T1 mouse breast cancer, LL2 mouse lung cancer, MCF-7 human breast cancer (luminal A phenotype) and MDA-MB-468 human TNBC (basal phenotype) cell lines were purchased from DS Pharma (Tokyo, Japan). The CT26 mouse colon cancer cell line was a kind gift from Professor I. J. Fidler (MD Anderson Cancer Center). The cell lines were maintained in DMEM (Sigma Chemical, St. Louis, MO, USA) containing 10% FBS (Sigma) in a 5% CO₂ atmosphere at 37°C. The following reagents were purchased: charcoal stripped FBS (Sigma), tamoxifen (TMX; Sigma), angiotensin I and II (A-I and II; Abgent, San Diego, CA, USA), angiotensinogen (ATG; Calbiochem, Darmstadt, Germany), angiotensin 1-7 (A1-7; California Peptide Research, Napa, CA, USA), cisplatin (CDDP; Alexis) and xanthenone (XTN; Alfa Aesar, Ward Hill, MA, USA).

**Cell treatment, cell growth, apoptosis and in vitro invasion assay.** The cells were treated with TMX (2 μg/mL), ATG (20 nM), A-I (1 ng/mL), A-II (1 ng/mL), A1-7 (100 nM) or CDDP (10 μM) for 24 h before analyses. Cells were seeded at a density of 10,000 cells per well in 12-well tissue culture plates. Cell growth was assessed by cell counting using an autocytometer (Sysmex, Kobe, Japan). Apoptosis was assessed by staining with Hoechst 33258 fluorescent dye (Wako Pure Chemical, Osaka, Japan). The number of apoptotic cells was determined by counting Hoechst 33258 stained nuclei. To confirm the specificity of antibody immunoreactivity, cardiac muscle and colonic mucosa specimens were counterstained with Meyer’s hematoxylin and diaminobenzidine (DAKO, Carpinteria, CA, USA), and the immunohistochemistry was performed as described previously.(24) MAS1 antibody (Novoceastra, Newcastle upon Tyne, UK) was used at a concentration of 0.5 μg/mL. Color development was performed using 3,3’-diaminobenzidine (DAKO, Carpinteria, CA, USA), and the specimen was counterstained with Meyer’s hematoxylin (Sigma) to visualize the nuclei. To confirm the specificity of antibody immunoreactivity, cardiac muscle and colonic mucosa were used as positive and negative controls, respectively. After

| Table 1. RT-PCR primer sequences |
|-------------------------------|
| Human | Forward primer | Reverse primer | Reference |
| MAS1 | tggctttctcttgcgcatt | gaccaatggcgacgtgtct | BC110454.2 |
| Mouse | catctagacgctgagcagc | agtccagaggtgagacca | NM_008552.4 |
| Cathepsin D | tccagagcgctctctggtta | ccaagatgctcatcaccat | NM_009983.2 |
| ACE2 | ctacagccctctcagaaag | tggccagagctcatgtgtt | AB053182.1 |
| CD10 | gaattacagccaaagaagc | tgcagtacgtaagagattg | BC034092.1 |
| ER1 | aagggagctcacaagtaacc | gcaggtcacttcccaccat | NM_007956.4 |
| PgR | ggtggaggtcgtacaagcat | ctcatgggtcacctggagtt | NM_008829.2 |
| HER2 | gctgtgctgatgctgtaga | ggcgaatgccgaagctggt | BC053078.1 |

ACE2, angiotensin converting enzyme 2; CD10, nephrilysin (cluster of differentiation 10); ER1, estrogen receptor 1; HER2, human epithelial growth factor receptor-related 2; PgR, progesterone receptor; RT-PCR, reverse transcriptase polymerase chain reaction.

| Table 2. Relationship between MAS1 expression and clinicopathological parameters of breast cancer samples |
|-----------------------------------------------|
| | N | MAS1 expression | Weak | Strong | P |
| Tissue type | | | | | |
| Benign tissue | | | | | |
| DCIS | 21 | 0 | 0 | 2 | 19 | |
| IDC | 10 | 0 | 0 | 3 | 7 | NS |
| papillotubular | 35 | 3 | 9 | 23 | 0 | |
| solid-tubular | 55 | 6 | 22 | 27 | 0 | |
| scirrhous | 42 | 15 | 19 | 8 | 0 | 0.0002 |
| Grade 1 | 53 | 4 | 18 | 31 | 0 | |
| Grade 2 | 37 | 4 | 15 | 18 | 0 | |
| Grade 3 | 42 | 16 | 17 | 9 | 0 | 0.0003 |
| pT1 | 55 | 1 | 21 | 33 | 0 | |
| pT2 | 41 | 7 | 17 | 17 | 0 | |
| pT3 | 21 | 8 | 6 | 7 | 0 | |
| pT4 | 15 | 8 | 6 | 1 | 0 | 0.0001 |
| pN0 | 104 | 1 | 45 | 58 | 0 | |
| pN1 | 28 | 23 | 5 | 0 | 0 | 0.0001 |

P-value was calculated by χ²-test. DCIS, ductal carcinomas in situ; IDC, invasive ductal carcinoma; NS, not significant.
immunostaining, all slides were assessed according to the immunoreactive score. This score was originally proposed for evaluation of ER expression, although it has also been used to evaluate membranous and/or cytosolic staining in many studies. The score was expressed as four grades: “none,” score 0; “trace,” score 1–2; “weak,” score 3–5; and “strong,” score 6–8.

**Reverse transcription-PCR.** Total RNA (1 μg) was synthesized using the ReverTra Ace quantitative PCR (qPCR) RT Kit (Toyobo, Osaka, Japan). The primer sets for amplification are listed in Table 1. The PCR conditions were set according to the provider’s instructions. PCR products were electrophoresed on a 2% agarose gel and visualized using ethidium bromide.

**Quantitative reverse transcription-polymerase chain reaction.** Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA) and total RNA (1 μg) was synthesized with the ReverTra Ace qRT Kit (Toyobo). Quantitative reverse transcription-PCR was performed using StepOne Plus Real-Time PCR Systems (Applied Biosystems, Foster City, CA, USA) using TaqMan Fast Universal PCR Master Mix (Applied Biosystems). The values were compensated by the relative standard curve quantification method. PCR condition was according to the manufacturer’s instructions and the ACTB mRNA level was amplified for internal control. TaqMan Gene Expression Assay of MAS1 was purchased from Applied Biosystems. PCR was done in triplicate.

**siRNA transfection.** FlexiTube siRNA for MAS1 was purchased from Qiagen Genomics (Bothell, WA, USA). AllStars Negative Control siRNA was used as a control (Qiagen). Cells were transfected with 50 nM siRNA for each gene using Lipofectamine 2000 (Invitrogen, Invitrogen Corp., Carlsbad, CA) according to the manufacturer’s instructions.

**ELISA and examination of ACE2 activity.** Frozen mouse tissues were sonicated in lysis buffer, and the supernatants were collected and used for ELISA. The concentrations of A1-7 and ACE2 were determined using the A1-7 ELISA kit (Cusabio Biotech, Wuhan, China) and the Sensolyte 390 ACE2 Activity Assay Kit (AnaSpec, Fremont, CA).

**Table 3. DCIS cases**

| Age | Grade  | MAS1 | ER | PgR | HER2 | MAS1 in IDC |
|-----|--------|------|----|-----|------|-------------|
| 30  | Low    | Strong | 2  | 1   | 2+   | Traceable   |
| 38  | Low    | Strong | 3  | 2   | 0    | Weak        |
| 48  | Intermediate | Strong | 3  | 3   | 1+   | NA          |
| 63  | Low    | Strong | 3  | 3   | 0    | Traceable   |
| 71  | Low    | Strong | 3  | 3   | 1+   | NA          |
| 47  | Intermediate | Strong | 3  | 1   | 2+   | Weak        |
| 38  | Intermediate | Strong | 2  | 2   | 1+   | None        |
| 45  | Low    | Weak   | 3  | 2   | 0    | Traceable   |
| 67  | High   | Weak   | 2  | 3   | 2+   | NA          |
| 58  | High   | Weak   | 3  | 3   | 2+   | NA          |

Estrogen receptor (ER) and progesterone receptor (PgR) were scored by J-Score system. Human epithelial growth factor receptor-related (HER2) was scored according to the Guide for HER2 Testing by Japanese Breast Cancer Society. NA, not applicable, no IDC was accompanied.
USA), respectively, according to the manufacturer’s instructions.

Statistical analysis. Statistical analyses of experimental data were performed using the Mann–Whitney U-test, analysis of variance and the $\chi^2$-test. Nonparametric correlations were examined using the Spearman rank correlation test. Statistical significance was defined as a two-sided $P$-value of $<0.05$.

Results

Expression of MAS1 in breast cancer. A total of 21 benign breast tissues, 10 DCIS and 132 IDC cases were examined by immunohistochemistry (Table 2). MAS1 expression was strongly observed in the benign mammary duct (Fig. 1a). In some cases, MAS1 expression was emphasized in the myoepithelial cells (inset). In Figure 1(b), the cribriform type DCIS expressed MAS1 at strong grade, whereas surrounding invading nests expressed MAS1 at traceable-weak grade. Scirrhous IDC and the lymph node metastasis expressed MAS1 at “none” grade (Fig. 1c,d). In Figure 1(e), solid-tubular type TNBC was shown, which expressed MAS1 at weak grade. Thus, MAS1 expression was repressed in the order from benign duct, DCIS to IDC, but not TNBC. The positive control, cardiomyocytes, showed very high MAS1 expression in the cytoplasm and plasma membrane (Fig. 1f), whereas colonic epithelium, and no primary antibody-staining as the negative controls, showed no MAS1 expression (Fig. 1g,h).

Relationship between MAS1 expression and clinicopathological parameters. The MAS1 expression levels in IDC were significantly lower than those in benign tissues (Table 2). However, DCIS did not show a significant reduction in MAS1 expression compared to the non-cancerous tissues. DCIS also showed MAS1 expression at higher grades than that of IDC ($P < 0.0001$). The six cases of 10 DCIS surrounded IDC (Table 3). Comparing the MAS1 expression between DCIS and IDC in the same tumor, the expression levels in IDC were lower than those in DCIS.

All histological types of IDC showed reduced MAS1 expression compared to non-cancerous tissues, with scirrhous carcinomas showing the most prominent reduction in MAS1 expression (Table 2). A decrease in MAS1 expression was associated with histological grade, tumor growth (T factor) and lymph node metastasis (N factor).

Relationship between MAS1 expression and molecular parameters. Next, the relationships between the expression levels of
MAS1 and various molecular markers, including the MIB-1 proliferation index and the expression of ER, PgR, epidermal growth factor receptor (EGFR) and HER2, were examined (Table 4). MAS1 expression was inversely associated with the MIB-1 proliferation index and EGFR and HER2 expression, whereas no association with the expression of the hormone receptors (ER and PgR) was noted.

Role of MAS1 in MCF-7 and MDA-MB-468 human breast cancer cells. The expression of MAS1 was examined in MCF-7 human breast cancer cells (luminal A phenotype) and MDA-MB-468 TNBC cells (basal phenotype) (Fig. 2a,b). MCF-7 cells expressed MAS1, which was increased by estradiol deprivation for 48 h. In contrast, estradiol deprivation did not affect MAS1 expression in MDA-MB-468 cells. MAS1 expression was decreased to a traceable level by knockdown in both cell lines. Referring to the observation, we examined the effect of MAS1 activation by A1-7 with or without TMX or MAS1 knockdown (Fig. 2c–f). MAS1 expression was increased by TMX treatment in MCF-7 cells but not in MDA-MB-468 cells. TMX alone and A1-7 alone showed inhibition of growth, survival and invasion in MCF-7 cells. Moreover, concurrent treatment of TMX and A1-7 showed synergic effects in MCF-7 cells. In contrast with MCF-7 cells, MDA-MB-468 cells showed that A1-7 treatment inhibited growth, survival and invasion, but TMX did not. The effects by A1-7 were abrogated by MAS1 knockdown. Thus, A1-7 treatment is effective in both non-TNBC and TNBC cells; however, a synergic effect with anti-estrogen treatment might be expected in non-TNBC cells.

Role of MAS1 in 4T1 mouse triple-negative breast cancer cells. The expression of MAS1 and other RAS factors was examined in 4T1 mouse breast cancer, LL2 mouse lung cancer and CT26 mouse colon cancer cells (Fig. 3a). The 4T1 cells were found to express MAS1 but not the A1-7 producing enzymes ACE2 and CD10. In contrast, LL2 and CT26 cells expressed ACE2 and CD10, whereas MAS1 expression was very low. Upon MAS1 knockdown, MAS1 expression disappeared in 4T1 cells (Fig. 3b). A-II and A-I, which were converted by cathepsin D expressed in 4T1 cells, were found to enhance the growth of these cells (Fig. 3c). In contrast, the growth of 4T1 cells was suppressed by A1-7 treatment. In the knockdown study, control siRNA-exposed 4T1 cells showed suppression of cell growth and invasion and induction of apoptosis upon A1-7 treatment (Fig. 3d–f); however, these effects were abrogated by MAS1 siRNA-treatment.

Expression of MAS1 in triple-negative breast cancer. Of the 132 cases of IDC, 12 (9.1%) showed no expression of ER, PgR and HER2, and were, hence, designated as TNBC.
Table 5. Expression of MAS1 in triple-negative breast cancer (a) Relationship between MAS1 expression and clinicopathological parameter in triple-negative breast cancer cases; (b) Triple negative cancer versus other cancer and (c) Relationship between MAS1 expression in TNBC tissue array cases

**Table 5a.** The 12 TNBC cases expressed MAS1 at “weak” grade, whereas 48 cases of the 120 non-TNBC cases expressed MAS1 at “weak” grade ($P < 0.0001$). Importantly, all TNBC expressed MAS1, although the levels of MAS1 expression in TNBC and non-TNBC samples did not differ significantly (Table 5b). Spearman’s correlation between MAS1 score and

|   |   |   |   |   |   |   |   |   |   |   |
|---|---|---|---|---|---|---|---|---|---|---|
| Age | Histology | Grade | pT | pN | ER (%) | PR (%) | HER2 | p53 (%) | EGFR | MIB1 (%) | MAS1 | MAS1 score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 48 | IDC | ST | 2 | 1 | 0 | 0 | 0 | 30 | Weak | 25 | Trace | 1 |
| 42 | IDC | ST | 1 | 2 | 0 | 0 | 0 | 60 | Moderate | 25 | Trace | 1 |
| 44 | IDC | SC | 3 | 3 | 1 | 0 | 0 | 55 | Weak | 25 | Trace | 2 |
| 36 | IDC | SC | 1 | 1 | 0 | 0 | 0 | 45 | None | 35 | Weak | 3 |
| 54 | IDC | SC | 2 | 1 | 0 | 0 | 0 | 20 | None | 5 | Weak | 3 |
| 44 | IDC | ST | 2 | 1 | 0 | 0 | 0 | 50 | Weak | 5 | Weak | 3 |
| 79 | IDC | PT | 2 | 2 | 0 | 0 | 0 | 20 | Moderate | 10 | Weak | 4 |
| 56 | IDC | SC | 3 | 2 | 0 | 0 | 0 | 20 | Weak | 15 | Weak | 3 |
| 49 | IDC | SC | 3 | 2 | 1 | 0 | 0 | 0 | None | 10 | Weak | 4 |
| 36 | IDC | PT | 2 | 3 | 1 | 0 | 0 | 15 | None | 15 | Weak | 5 |
| 56 | IDC | ST | 2 | 4 | 1 | 0 | 0 | 70 | None | 40 | Weak | 5 |
| 37 | IDC | ST | 3 | 4 | 1 | 0 | 0 | 95 | Weak | 60 | Weak | 5 |

$P$-values: Nonparametric correlations were examined using the Spearman rank correlation test. (b) $P$-values were calculated by Mann–Whitney $U$-test** or **$\chi^2$-test. (c) $P$-values were calculated by Mann–Whitney $U$-test or **$\chi^2$-test. EGFR, epidermal growth factor receptor; ER, estrogen receptor; HER2, human epithelial growth factor receptor-related; IDC, invasive ductal carcinoma; NS, not significant; PR, progesterone receptor; PT, papillotubular; SC, scirrhous; ST, solid tubular.

© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.
clinopathological parameters was calculated for the role of MAS1 in progression of TNBC cases. As shown in Table 5(a), MAS1 expression was correlated with pT and pN.

To confirm the MAS1 expression in TNBC, we analyzed the tissue array specimens. The 36 cases of triple-negative IDC were subjected to comparison of MAS1 expression with the clinopathological parameters (Table 5c). All cases expressed MAS1 at score 1–5 levels (i.e. traceable to weak), which were correlated with pT, pN and stage.

The 4T1 cell line did not express ER, PgR and HER2, which meant that the cells were classified as TNBC (Fig. 3b). In the syngeneic BALB/c mouse model, MAS1-knockdown of 4T1 cells resulted in increased tumor growth in the mammary pads and lung metastasis by tail vein inoculation (Fig. 4a,b). CDDP has been reported to be effective against TNBC in clinical studies, and, accordingly, we used CDDP as a chemotherapeutic agent in this study. In the in vitro study, CDDP or A1-7 treatment resulted in mild growth inhibition, whereas CDDP plus A1-7 co-treatment showed synergic inhibitory effects in 4T1 cells exposed to control siRNA (Fig. 4c). In contrast, only CDDP showed an effect in 4T1 cells transfected with MAS1 siRNA. In the mouse model, XTN, an ACE2 activator, was used for activation of MAS1 (Fig. 4d). Since CDDP and XTN treatment both inhibited tumor growth individually, co-treatment with CDDP and XTN showed additive effects on growth inhibition in cells treated with control siRNA. In contrast, the tumors in mice treated with MAS1 siRNA were larger than those in mice treated with control siRNA, and CDDP showed less pronounced inhibitory effects in these mice.

In the last set of experiments, we examined concurrent treatment with XTN and angiotensin II type 1 receptor blocker (ARB) (Fig. 4e). ARB plus XTN treatment showed more pronounced inhibitory effects than XTN treatment alone. Moreover, CDDP plus ARB plus XTN showed synergic inhibitory effects, which were even more pronounced than the treatments with CDDP alone or CDDP plus XTN.

Fig. 4. Effect of MAS1 targeting on the antitumoral activity of cisplatin (CDDP) in a mouse tumor model. (a, b) Tumors were treated with MAS1 siRNA. (a) Tumor size after 4T1 tumor cell inoculation in the mammary pad. (b) Number of metastatic foci in the lungs from 4T1 cells inoculated in the tail vein. (c) In vitro treatment of 4T1 cells with CDDP and/or angiotensin 1-7 (A1-7) and control or MAS1 siRNA. (d) In vivo treatment of 4T1 cells in the mouse mammary pad with CDDP and/or xanthenone and control siRNA or MAS1 siRNA. (e) Tumor growth by intramammary inoculation of 4T1 cells. (f) Angiotensin converting enzyme 2 activity and A1-7 concentration in inoculated 4T1 cells and the surrounding stromal cells of the mammary pads. ARB, losartan. P was calculated from three independent experiments or five mice by Mann–Whitney U-test.
To elucidate the effects of XTN, tumor cells and the surrounding mammary stromal cells were separately examined for ACE2 activity (Fig. 4f). In tumor cells, ACE2 activity was not significantly increased by XTN, whereas stromal cells showed marked increases in ACE2 activity by XTN.

Discussion

In the present study, MAS1 expression was found to be inversely associated with histological type, grade, tumor growth (T factor) and nodal metastasis (N factor). These findings suggest that MAS1 may possess tumor-inhibitory properties. The in vitro findings supported these results, with MAS1 knockdown resulting in increased 4T1 cell growth, survival and invasion. Thus, reduced MAS1 expression might be a relevant marker for the malignant potential of breast cancer.

MAS1 is expressed in non-cancerous breast tissues; however, here, we found that the expression was significantly decreased in most IDC cases. The cause of MAS1 repression has not been elucidated. In contrast, MAS1 is upregulated in CRC tissue compared to non-cancerous mucosa. Moreover, in breast cancer, MAS1 shows antitumoral effects, whereas in CRC, MAS1 has been demonstrated to be refractory to A1-7 and A-II. Genomic mutations or intracellular signal alterations might explain the differences in MAS1 expression and activity between these malignancies. Under normal conditions, MAS1 produces a functional complex with the other A-II receptors, AT1R and AT2R, to maintain vascular homeostasis. Certain cancers might result in deviations in vascular homeostasis by causing an imbalance in the expression of the angiotensin-related receptors.

Importantly, in the present study, MAS1 expression was retained in TNBC compared to non-TNBC. The 4T1 mouse breast cancer cell line showed no ER, PgR or HER2 expression, which indicates that it is a TNBC cell line. MDA-MB-231 breast cancer cell line showed no ER, PgR or HER2 expression-related receptors.

In our animal model, we used XTN to activate ACE2, which converts A-II to A1-7. ACE2 activity was observed in the normal mammary pad tissue along with A1-7. Two weeks after inoculation in the animal model, no synergism was detected. We also treated the mice with ARB in addition to XTN and CDDP to increase the levels of A1-7 by conversion from A-II by ACE2. We examined an MCF-7 human breast cancer cell line possessing a luminal A phenotype. Interestingly, estrogen starvation from medium upregulated MAS1 expression in MCF-7 cells. TMX treatment also upregulated MAS1 expression, which inhibited cell growth, survival and invasion in synergism with MAS1 activation by A1-7. In rat pups, estradiol upregulated MAS1 in the brain; however, no reports were found on the effect of sex hormone on MAS1 expression in mature tissues or tumors. In our IDC cases, no correlation was detected in the expression levels between ER and MAS1 (data not shown). The precise mechanism requires further examination; however, anti-estrogen therapy might provide a synergic effect with MAS1 targeting in non-TNBC cases.

In the present study, MAS1 activation by A1-7 resulted in inhibition of cell growth, invasion and anti-apoptotic survival. MAS1 is a G-protein coupled receptor, which intracellular signal pathways are suppressing extracellular signal-regulated kinases1/2 (ERK1/2) and nuclear factor κB. MAS1 is known to activate Src homology 2-containing inositol phosphatase 2 (SHIP2), which inhibits activation of EGFR ERK1/2. Because TNBC have been reported to highly express EGFR as a basal phenotype, EGFR is one of the molecular targets in TNBC. Anti-EGFR activity of MAS1 might suggest that a combination molecular targeting of MAS1 and EGFR is relevant for TNBC treatment.

ATR2 shows also anti-angiotensin-II activity. The anti-tumoral effect of MAS1 was not affected by A-II, whereas ATR2 showed a biphasic effect; pro-tumoral in low A-II concentration and anti-tumoral in high A-II concentration. Interestingly, MAS1 expression was emphasized in the myoepithelial cells, or basal cells. Silencing of basal phenotype-associated FoxM1 decreases MAS1 expression. That possibly suggest that MAS1 expression might be associated with myoepithelial, or basal phenotype. In the myocardial cells express MAS1 by hypomethylation of MAS1 gene promoter. Silencing of DNA methyltransferase 3a or tripartite motif protein 28 also causes MAS1 overexpression by epigenetic dysregulation. Association of MAS1 expression with basal phenotype might explain the cause of MAS1 expression in TNBC, many of which bring basal phenotype. The cause of MAS1 repression in breast cancer has not been elucidated; however, epigenetic alteration and basal differentiation might be key subject in future study.

In the present study, we showed that activation of MAS1 could be achieved by ACE2 activation, which is enhanced by co-treatment with ARB, and that MAS1 activation resulted in increased CDDP antitumoral effects. MAS1 is a possible molecular target in breast cancer, including TNBC.

Acknowledgment

This work was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, Japan and a Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare of Japan.

Disclosure Statement

The authors have no conflict of interest to declare.

References

1 Escobar E, Rodriguez-Reyna TS, Arrieta O, Sotelo J. Angiotensin II, cell proliferation and angiogenesis regulator: Biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2004; 2: 385–99.
2 Kuniyasu H. Multiple roles of angiotensin in colorectal cancer. World J Clin Oncol 2012; 3: 150–4.
3 Fyhrquist F, Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 2008; 264: 224–36.
4 Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005; 16: 203–99.
5 Shimomoto T, Ohmori H, Luo Y et al. Diabetes-associated angiotensin activation enhances liver metastasis of colon cancer. Clin Exp Metastasis 2012; 29: 915–25.
6 Luo Y, Ohmori H, Shimomoto T et al. Anti-angiotensin and hypoglycemic treatments suppress liver metastasis of colon cancer cells. *Pathobiology* 2011; 78: 285–90.
7 Zhou L, Luo Y, Sato S et al. Role of two types of angiotensin II receptors in colorectal carcinoma progression. *Pathobiology* 2014; 81: 169–75.
8 Campbell DJ. Vasopressinase inhibition: a double-edged sword? *Hypertension* 2003; 41: 383–9.
9 Regulska K, Stanisz B, Regulski M. The renin-angiotensin system as a target of novel anticancer therapy. *Curr Pharm Des* 2013; 19: 7103–25.
10 Johansson A, Helou K, Levan G. Cytogenetic localization of cancer-related genes in the rat and comparative mapping studies in human and mouse. *Cytogenet Cell Genet* 1998; 81: 217–21.
11 Bernardi S, Zennaro C, Palmisano S et al. Characterization and significance of ACE2 and Mas receptor in human colon adenocarcinoma. *J Renin Angiotensin Aldosterone Syst* 2012; 13: 202–9.
12 Wakao F, Nishimoto H, Katanoda K, Tsukuma H, Mikami H. eds. *Cancer Statistics in Japan*, 2013, 2013 edn. Tokyo: National Cancer Center, 2013.
13 Yagata H, Kajiura Y, Yamauchi H. Current strategy for triple-negative breast cancer: appropriate combination of surgery, radiation, and chemotherapy. *Breast Cancer* 2011; 18: 165–73.
14 Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. *Breast* 2010; 19: 312–21.
15 Bagaria SP, Ray PS, Sin MS et al. Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. *JAMA Surg* 2014; 149: 125–9.
16 Brady-West DC, McGrowder DA. Triple negative breast cancer: therapeutic and prognostic implications. *Asian Pac J Cancer Prev* 2011; 12: 2139–43.
17 de Ruiter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. *J Cancer Res Clin Oncol* 2011; 137: 183–92.
18 Chekhun S, Bezdenzhykh N, Shvet S, Lukianova N. Expression of biomarkers related to cell adhesion, metastasis and invasion of breast cancer cell lines of different molecular subtype. *Exp Oncol* 2013; 35: 174–9.
19 Kuniyasu H, Luo Y, Fuji K et al. CD10 enhances metastasis of colorectal cancer by abrogating the anti-tumoural effect of methionine-encephalin in the liver. *Gut* 2010; 59: 348–56.
20 Kuniyasu H, Oue N, Wakikawa A et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. *J Pathol* 2002; 196: 163–70.
21 Chihara Y, Fujimoto K, Kondo H et al. Anti-tumor effects of liposome-encapsulated titanium dioxide in nude mice. *Pathobiology* 2007; 74: 353–8.